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Steroid hormones and receptors:
Steroid hormones are an important class of regulatory ligands which involve intracellular 
receptor sites that interact with the genome. There are three main types of steroid hormones: 
the sex steroids, which are further subdivided into androgens, progestins, and estrogens, 
adrenal steroids, which consist of the glucocorticoids and the mineralocorticoids, and vitamin 
D3.1 Metabolic transformations of these steroids, especially of the androgens, are important 
modes of regulation as these transformations produce either more or less active metabolites. 
Vitamin Da's main role is calcium metabolism and bone development and its major 
transformation to an active metabolite occurs in the kidney and the liver. The sex steroids, as 
the name implies, regulate the development of secondary sex characteristics, and are also 
capable, with metabolic transformation in the nervous system, of governing neuronal 
excitability and dopamine release in the brain.2 Corticosteroids too play a very significant role 
in the central nervous system. Corticosteroid receptors are divided into three main types, the 
mineralocordcoid and corticosterone-preferring (Type 1) and the glucocorticoid receptors (Type 
II). The importance of the adrenal steroids lies in their ability to mediate the stress response 
and maintain mineral balance (see Figure I). The mechanism of steroid hormone action is not 
definitive at this time. When circulating in the blood, steroids are generally attached to steroid 
binding proteins. The steroid then diffuses through the target cell membrane either passively or 
by facilitated transport. It is not known3 whether the location of the steroid receptors is nuclear 
or cytoplasmic. There are several theories regarding the effects of the steroid binding to the 
receptor, one of which is that the binding induces a conformational change in the DNA strand 
to allow transcription to commence.4
Figure I. 5
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MINERALOCORTICOID (MR)
Affinity: Aldosterone (K^-O.5-3 nM), -corticosterone (CORT) 
Localization: Circumventricular organs 
Function: Control of salt appetite
CORTICOSTERONE * PREFERRING (CR)
Affinity: Corticosterone (Kj~0.5 nM), aldosterone >dexamethasone 
Localization: Hippocampus CA, > dentate gyrus > CAS > la t  septum 
Function: Mediates tonic influences of CORT, index of brain aging
Type II
GLUCOCORTICOID (GR)
Affinity: Dexamethasone > corticosterone (K/-5.0 nM) > aldosterone 
localization: Hippocampal, thalamic, hypothalamic, cortical regions, glia 
Function: Mediation of stress response
Steroid hormones and breast cancer
For breast cancer, the receptors which have the most clinical significance are the 
progestin (PgR) and the estrogen receptors (ER). The presence or absence of these steroid 
receptors in a malignant breast tumor may be used as a prognostic tool and a  guide to therapy.3 
Currently, ER presence or absence is what is usually assessed and the typical method of 
detection used is the DCC (dextran-coated charcoal) method, which involves incubating a cell 
homogenate from biopsied tissue with radiolabelled (with tritium or M 2S) hormone.6 
Theoretically, the presence of ER indicates that the patient will respond to endocrine therapy, 
such as treatment with an antiestrogen like TAM (tamoxifen), however, die actual response m e  
of patients with ER+ tumors is only 50»55%.7** ER-negativity is a better indicator, as only 
10% o f ER* tumors respond favorably.9 The commonly accepted reasons for the lack of
correlation are heterogeniety of receptor distribution in the cells o f the tumor10 and the 
uncertainty of the souce of the receptor in the biopsy tissue, i.e. whether it is the tumor or 
surrounding epithelium. The DCC method can be improved by testing for PgR-positivity as 
PgR content is a better prognostic test than ER content, and when both test are used the 
correlation between PgR and ER-posidvity and endocrine therapy responsiveness becomes 
more acceptable. However, the DCC method also suffers from other disadvantages, for 
example small tumors may not provide enough tissue for an accurate assay and the analyzed 
tissue is consumed in the assay. Breast turnon may evolve from ER+ to ER' during the course 
of the illness, and ER content can vary with the menstrual cycle, which often requires many 
assays to be performed.11 The need to execute the assay repeatedly makes the relative 
invasiveness (need for a biopsy) of the DCC method even less desirable.
Positron emission tomography and breast cancer:
PET is a noninvasive, in vivo imaging method which employs radiotracers that are injected 
into the patient's bloodstream and the distribution of the tracer is measured by external 
detectors. A positron-emitting nuclide (usually n C, 13N, 150 , or 18F) is introduced into the 
desired ligand by radiochemical synthesis. The short half-lives of these isotopes requires a 
cyclotron to produce the radionuclides on demand and a brief synthesis of the tracer, however, 
the advantage of the short half-life is that the patient receives a limited exposure to the radiation. 
Positron emission occurs when there is a conversion of a proton to a neutron in a neutron- 
deficient nucleus. The positron possesses the properties of an electron except that it is 
positively charged, and when it is combined with an electron, a matter-antimatter annihilation 
occurs with the release of energy in the form of two high energy photons. The high energy 
photons are detected by coincidence circuits placed around the patient. The nature of the 
positron decay, which produces two photons which leave the annihilation site in opposite 
directions, allows for signal processing to generate good resolution.
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Many radiopharmaceuticals have been developed for use in PET, but most are either 
nonspecific ligands, such as H2150  for the evaluation of flow-related phenomena, or target 
brain receptor systems such as the dopaminergic, muscarinic, and opiate systems.12 Another 
approach is to use radiolabelled steroid hormones as the tracers, which utilizes the selective 
binding of these hormones to receptors to direct the ligand to a specific target tissue. For 
instance, 18F-labelled estrogens in conjunction with PET can be used for assessment of steroid 
receptors in human breast carcinoma.13 A method using estrogens and progestins is superior 
to the aforementioned DCC assay in that it is a noninvasive and performed in vivo. Ideally, all 
the steroid hormone receptors systems could be exploited for various clinical diagnoses with 
PET by the use of the appropriate radiolabelled steroid hormone. For example, a radiolabelled 
androgen could be used to assess prostatic carcinoma, or a corticosteroid could aid in the 
diagnosis of pituitary disorders.
Alzheimer's dementia (AD) and steroid hormones:
AD is the most common form of dementia in late life as it exists in approximately 7% of the 
population over age 65, and accounts for two-thirds of the cases of senile dementia.14 
Outwardly, the signs of AD are loss of cognitive functions, most markedly in memory, 
language, and orientation functions, although in the later stages of the disease personality, 
judgment, problem-solving, calculation, and motor abilities may be affected. A general 
observation of the AD brain shows marked atrophy, particularly in the hippocampus and the 
cortex. Microscopic examination reveals the histopathological hallmarks of the disease: the 
neuritic plaques, the neurofibrillary tangles, and granulovacular degeneration. These lesions 
are found in distinct areas of the brain, primarily in the cortex or limbic system, and 
secondarily in the hippocampus, amygdala, and the nuclei providing the cholinergic interaction 
between the cortex and the hippocampus (such as the basal nucleus of Meynert).15
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Many theories as to the causers) of AD have been advanced (a brief discussion of which are 
described elsewhere)16 such as viral injection,17 aluminosilicate toxicity,11 lack of trophic 
factors,19 and excessive production of excitotoxic amino acid neurotransmitters such as 
glutamate.20 The mechanism of the latter would involve the action of these amino acids on 
neurons weakened by continuous exposure to hypersecretion of endogenous 
glucocorticoids.21*22 If this were the case, the areas most affected by the neurotoxicity of 
elevated glucocorticoid levels are those containing glucocorticoid receptors, i.e. primarily in the 
hippocampus.23 The hippocampus also utilizes glutamate and is responsible for feedback 
inhibition of the production of corticosteroids. The result of the loss of hippocampal neurons 
is thus a disinhibition of glucocorticoid receptors by unabated production of corticosteroid 
leading to even higher concentrations of glucocorticoids, and leading to a "feed-forward 
cascade"21 of neuronal death (see Figure II). Because AD destroys these corticosteroid 
receptors, if app ropriate 18F-labelled mineralocorticoids and glucocorticoids are synthesized, 
the amounts of Type I and Type II corticosteroid binding proteins destroyed could be 
determined using PET, providing a diagnostic test for AD. Analogous to the PET scan for a 
breast tumors, PET with corticosteroids would provide a non-invasive, In vivo test for the 
disease, and because the brain is the area affected by AD, the non-invasiveness becomes 
imperative. The area of the brain visualized would depend on the type of corticosteroid used, 
primarily the hippocampus with the mineralocorticoids, and a more xen&ral image with the 
glucocorticoids. The technique of using receptor binding sights in the brain to binding an 
imaging agent might also be useful in other dementia that affect a brain receptor system, such 
dopamine receptors in Parkinson's dementia.24
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Results and Discussion
Estrogen. The lip-ethyl-16a-fluoroestradiol (17) was prepared from 1-dehydro- 
adrenosterone (1) in 16 steps as shown in Schemes I and II. The ketone at C-17 was 
selectively protected with ethylene glycol in refluxing benzene using a catalytic amount of p- 
toluene sulfonic acid monohydrate. The bulky lithium tri-f-butoxyaluminum hydride was 
employed to reduce the ketone at C-l 1 diastereoselectively. Reductive aromatization using 
lithium, biphenyl and diphenylmethane (to scavenge the methylithium formed) gave the 
aromatic A-ring. The newly-formed hydroxyl at C-3 was then protected as the methyl ether 
using methyl iodide with potassium carbonate as the base. Next the hydroxyl at C -11 was
Scheme I
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oxidized with Jones reagent and the product of this reaction was used without further 
purification due to its instability. Addition of EtLi at -78°C to the 11-ketone and addition of 
HC1 upon wanning gave the 1 la-ethyl (7) compound by EtLi attack from the less hindered 
side and effected deprotection at C-17. The steroid was then dehydrated by treatment with 
refluxing benzene and tosic acid for 10 min. to give the 9,11-dehydro adduct (8). 
Hydrogenation of the double bond with H2 over Pd/C gave a 2.6:1 of l ip -  (9) to 1 la-ethyl 
epimers, whose absolute stereochemistry was confirmed by single crystal x-ray analysis. 
These epimers proved difficult to separate; however, after deprotection of the methyl ether with 
boron trifluoride-methyl sulfide complex, they could be separated by fractional 
recrystallization. 1 lp-Ethyl estrone (10) could be recrystallized from acetone/hexane while 
1 la-ethyl estrone remained soluble. The remainder of the steps in the sequence were carried 
out by another worker in this laboratory.16
A summary of the data for the binding assays of lip-ethyl-16a-flun>restradiol (17) is 
shown in Table I. The RBA's (relative binding affinities) were ascertained in vitro through a 
competitive
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Table I. Binding Data for 11^ -ethyl estradiols
RBA*1 NSB*2 BSI*3
25°C (0°C)
16o-protio 1120(117) 2.63 429
16a-fluoro 891 (128) 1.83 482
*lEstradiol = 100 
^Estradiol ■ 1 
*3Estradiol = 100
radiometric binding assay, using rat uterine cytosol as a source of ER, and [3H]estradiol as the 
tracer.23 NSB is an acronym for non-specific binding and BSI (binding selectivity index) is 
the quotient RBA/NSB. In preparing the 1 ip-ethyl derivative of fluoro-estradiol, it was hoped
that it would have a greater BSI than the parent compound. As can be seen from the data, that
result was achieved.
Next the tissue distribution of the radiolabelled [18F]-containing compound was determined 
in vivo. The studies were performed at the Mallinckrodt Institute of Radiology of Washington 
University Medical School, St. Louis, MO. The ,8F was produced in a cyclotron by 
bombardment of ,80-enriched water via the 180(p , n)18F reaction. The hot fluoride was dried 
by azeotropic removal of water (CH3CN) to render it more nucleophilic during subsequent 
reaction in an appropriate solvent. TBAF was used as the phase transfer catalyst in the 
resolubilization. The triflate precursor (15) was chosen so displacement would occur rapidly, 
necessitated by the short 18F half-life. After displacement, the 17-ketone was reduced by 
treatment with lithium aluminum hydride. After workup, the product was purified by HPLC 
employing both a radiation and a UV detector. Ideally, the radioactivity peak corresponding to 
the desired product should not correspond to any mass peak, as limiting amounts of fluoride 
are being used (see HPLC trace). After purification, the uptake studies were performed by the 
St. Louis group employing a method similar to that used for ltia-f^Flfluoroestradiol.26 The 
results of the biodistribution study are summarized in Table n . To verify that the uptake was 
mediated by a high-affinity, saturable system, one set o f animals was given a high dose of the 
unlabeled compound together with the labeled estrogen. The dose given was enough to 
saturate the estrogen receptors of the animal and should then block the optake of the labeled 
compound ( lh  blocked). The uncertain that target tissue uptake of 1 ip -ethy l- 16a- 
[18F]fluoroestradiol was not being limited by undetected ER-binding impurities, one set of 
animals was injected with a smaller amount of the radioactive ligand ( lh  low dose).
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Table II. Tissue Untake of 11 B-cthvl-16fl-l E%lUQTOCStradiol
1 5
Tissue
%lD7g ± SEM* (n = 5)
Ih
(high dose)
lh
(low dose)
lh
(blocked)
3h
(high dose)
Uterus 12.59 ± 3.40 13.50 ±3.26 0.48 ±0.15 11.49 ±2.11
Ovaries 5.62 ± 1.41 5.08 ± 0.66 0.76 ± 0.27 4.61 ± 0.70
Blood 1.09 ±0.46 0.82 ± 0.11 1.10 ±0.23 0.84 ± 0.55
Muscle 0.75 ±0.15 0.82 ±0.15 0.24 ± 0.09 0.39 ± 0.03
Lung 0.99 ± 0.23 1.35 ±0.37 0.92 ±0.18 0.71 ±0.07
Brain 0.17 ±0.04 0.13 ±0.04
Liver 3.31 ±2.12 1.94 ±0.57 3.35 ± 1.50 2.47 ± 0.90
Kidney 4.05 ±  2.40 3.29 ± 0.65 3.06 ± 1.16 2.52 ± 0.87
Fat 2.27 ±  0.88 1.42 ±0.04 1.86 ±0.43 0.98 ±0 .16
Bone 0.44 ±0.10 0.51 ±0.18 0.38 ±0.13 0.35 ±0.17
Uterus/Blood 12.99 ±2.11 16.60 ± 3.40 0.52 ±0.19 13.70 ±2 .80
Uterus/Muscle 16.97 ± 4.50 17.20 ± 6.30 2.12 ±0.59 32.50 ± 5.70
*SEM is standard error of the mean.
Progestins. The 21-fluoro derivatives of R5020 were easily prepared in four steps as 
shown in Scheme III from the corresponding optically pure starting material (21/?-fluoro (27) 
from RU27987 (19) and 21S-fluoro (28) from RU27988 (20)). The cyclic ketal was formed at 
C-3 with ethylene glycol employing a catalytic amount of tosic acid and triethylorthoformate as 
a dehydrating agent. The 21-trifluoroniethaResulfonate was then prepared by addition of triflic 
anhydride and 2,6-lutidine to a methylene chloride solution of the steroid (21 or 22). Fluoride 
displacement of the triflates (23 and 24) was effected with TBAF and the ketal protecting group 
was subsequently removed with concentrated sulfuric acid in acetone.
The RBA's of compounds 27 and 28 were measured relative to R5020 utilizing E2-primed 
rat uterine cytosol. The radiochemical synthesis of the l8F-labelled compounds was performed 
in a method similar to that of 1 l|3-ethyl-16a-[18F]fluoroestradiol, except after fluoride 
displacement, the ketal at C-3 was deprotected with concentrated sulfuric acid. After 
purification by HPLC (see trace) only the 21S-,8F epimer was subjected to the
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Scheme III. Synthesis of 21-Fluon) R5Q20
21R- RU27987 (19) 
2 IS- RU27988 (20)
nBu4NF
THF
RBA
21R-F 11 
21S-F 50 
21-H 100
21R- (27), 63% 
21S- (28), 63%
Table IU. Tissue Uptake of 21S-fF1% uoroR5020 (n = 5)
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%ID/gram
1 hour* 
low
1 hour 
high
1 hour 
blocked
3 hour 
high
Blood 0.338 ± 0.072 0.481 ± 0.071 0.329 ± 0.013 0.119 ±0.026
Liver 1.79 ±0.344 2.46 ±0.449 1.86 ±0.204 0.905 ± 0.239
Spleen 0.337 ± 0.047 0.423 ± 0.099 0.300 ± 0.025 0.103 ±0.015
Kidney 0.700 ±0.118 0.976 ±0.186 0.684 ± 0.057 0.247 ± 0.047
Muscle 0.366 ±0.189 0.508 ±0.147 0.389 ±0.162 0.117 ±0.034
Brain 0.278 ± 0.059 0.398 ±0.115 0.261 ± 0.024 0.088 ± 0.021
Bone 7.14 ±1.67 10.24 ±2.64 6.24 ±0.901 13.68 ±2.25
Uterus 1.47 ±0.484 2.07 ±0.276 0.283 ± 0.027 0.387 ± 0.091
Ovaries 1.35 ±0.371 2.01 ±0.549 1.04 ±0.144 0.511 ±0.133
%ID/organ
Blood
Liver
Spleen
Kidney
Muscle
Brain
Bone
Uterus
Ovaries
1.36 ±0.378 
5.07 ±0.956 
0.083 ± 0.023 
0.239 ± 0.049 
2.95 ±1.59 
0.375 ± 0.086 
44.60 ±11.83 
0.145 ±0.052 
0.039 ± 0.012
1.94 ±0.311 
7.09 ±0.410 
0.089 ± 0.019 
0.317 ± 0.057 
4.14 ±1.32 
0.525 ± 0.174 
63.26 ±10.21 
0.199 ±0.050 
0.062 ± 0.022
1.50 ±0.104 
5.84 ±0.896 
0.081 ±0.015 
0.250 ± 0.036 
3.52 ±1.38 
0.367 ± 0.050 
44.37 ±6.67 
0.031 ±0.003 
0.034 ± 0.006
0.528 ±0.119 
2.65 ±0.651 
0.029 ± 0.010 
0.090 ±0.016 
1.04 ±0.319 
0.122 ±0.032 
93.55 ±5.53 
0.043 ± 0.019 
0.015 ±0.004
Uterus/blood 4.275 ± 0.544* 4.328 ± 0.340 0.860 ± 0.073 3.294 ± 0.523
Uterus/muscle 4.476 ± 1.664 4.359 ± 1.373 0.857 ± 0.394 3.386 ± 0.507
Ovaries/blood 4.009 ± 0.953 4.150 ±0.716 3.153 ±0.447 4.363 ± 0.778
Ovaries/muscle 4.075 ±1.391 4.083 ±1.13 3.314 ± 2.052 4.519 ±0.980
*n = 6
biodistribution assay, as the 2 l/?-,8F epimer had a prohibitively low RBA. The results of that 
study are summarized in Table III.
Glucocorticoid. The fluoro analog of RU28362 (35) was conveniently prepared from 6a- 
methylpredinsolone (29) in 6 steps as depicted in Scheme IV. Cleavage at C-17 with sodium 
bismuthate gave the 17-ketone, which was followed by chloranil desaturation to give the A6-7 
olefin. Next, propargyltetrahydropyranyl ether was added at C -ll and the THP ether was 
cleaved with HOAc in water and THF to give a 3' hydroxyl. The hydroxyl was then converted
2 0
Scheme IV. SYNTHESIS OF FLUQRQ r RU28362
HO » l ,C - C C H 2OH
CH3S 02C1
(59%)
HO ^ C - C C H 2S02CH3
n-Bi^NF
(70%)
O
RU28362 100 11 nM
F-RU28362 29 38 nM
SCS 0043-1
SCCH 2
to the mesylate with mesyl chloride and displacement of the mesylate with TBAF gave fluoro- 
RU28362 (35).
The RBA of com pound 32 was measuted relative to RU28362 utilizing liver cytosol from 
adrenalectomized rats as the receptor source. The radiochemical synthesis of the 18F-labelled 
compounds was performed in a method similar to that of 1 ip-ethyl-16a-[18F]fluoroestradiol, 
except a mesylate was used ?s the leaving group rather than a triflate. After purification by 
HPLC (see trace) the biodistribution assay was performed. The results of that study are 
summarized in Table IV.
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Table IV. Tissue Uptake of figF1fluoroRU28362 (n = 4)
%ID/gram
15 min 1 hour* 1 hour 
blocked
2 hour
Blood 0.394 ± 0.049 0.309 ± 0.026 0.216 ± 0.033 0.308 ±  0.05
Liver 2.314 ± 0.257 1.65 ±0.242 1.035 ±0.195 1.487 ±0.21
Kidney 1.287 i  0.187 0.964 ± 0.08 0.68 ±0.216 0.869 ±0.110
Muscle 0.403 ± 0.049 0.323 ± 0.015 0.209 ± 0.04 0.300 ±  0.037
Fat 0.892 ± 0.332 0.658 ± 0.083 0.382 ± 0.062 0.634 ±0.112
Striatum 0.139 ±0.016 0.128 ± 0.01 0.077 ± 0.009 0.139 ±0.024
Cerebellum 0.151 ±0.014 0.132 ± 0.014 0.086 ± 0.008 0.141 ±0.024
Cortex 0.143 ±0.010 0.125 ±0.012 0.075 ± 0.007 0.131 ±  0.02
Hippocampus 0.120 ±0.014 0.115 ±0.013 0.078 ± 0.003 0.125 ±0.021
Hypothalamus 0.134 ±0.022 0.114 ±0.023 0.095 ±  0.019 0.166 ±0.04
Rest of brain 0.135 ±0.011 0.124 ±0.011 0.08 ±0.008 0.137 ±0.023
Total Brain 0.138 ±0.012 0.125 ± 0.012 0.08 ±0.007 0.137 ±0.023
Bone 0.438 ± 0.053 1.27 ±0.279 2.73 ±0.287 1.51 ±0.137
%ID/organ
Blood 5.41 ±0.256 4.10 ±0.239 2.865 ± 0.201 4.13 ±0.321
Liver 18.67 ±1.81 12.54 ±0.622 7.70 ±0.493 13.03 ±2,19
Kidney 1.095 ±0.038 0.766 ± 0.045 0.591 ±0.168 0.73 ±0.05
Muscle 11.15 ±1.276 8.59 ±0.442 5.55 ±0.679 8.09 ±0.375
Fat 23.75 ±7 .54 17.27 ±2.54 10.07 ±1.65 16.80 ±1.74
Rest of brain 0.179 ±0.019 0.172 ±0.021 0.111 ±0.013 0.186 ±0.028
Total brain 0.244 ± 0.032 0.231 ± 0.029 0.153 ±0.015 0.255 ±  0.042
Bone 9.39 ±0.537 26.26 ±5.28 56.65 ±2 .02 32.05 ±4 .66
*n = 5
As can be seen from the table, the specific uptake of [F-18JRU28362 in the hippocampus was 
not demonstrated. In order to ascertain a reason for this low target tissue selectivity (i.e. in 
vivo defluorination) die study was repeated using [3H]RU28362 as the radioactive ligand. The 
results of this study are summarized in Table V and Figure III.
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Table V. Tissue Uptake of 1*H1RU28362 In = 4)
15 min 1 hour 1 hour 1 hour 3 hour
%ID/gram blocked intact*
Blood
Fat
Musc;e
Kidney
Spleen
Liver
Lung
Thymus
Pituitary
Hippocampus
Cortex
Rest of brain
0.189 ±0.039 
0.302 ± 0.083 
0.251 ±0.062 
0.847 ±0.173 
0.429 ±0.105 
1.567 ±0.358 
0.772 ±0.179 
0.419 ±0.110 
1.111 ±0.246 
0.159 ±0.040 
0.183 ±0.042 
0.191 ±0.064
0.190 ±0.011 
0.593 ± 0,028 
0.371 ±0.026 
0.798 ± 0.062 
0.484 ± 0.076 
1.541 ±0.100 
0.544 ± 0.088 
0.525 ± 0.067 
1.008 ± 0.111 
0.162 ±0.013 
0.168 ± 0.011 
0.184 ±0.002
0.189 ±0.017 
0.587 ± 0.074 
0.362 ± 0.048 
0.683 ± 0.096 
0.414 ±0.066 
1.605 ±0.077 
0.436 ± 0.063 
0.414 ±0.071 
0.593 ± 0.042 
0.147 ±0.009 
0.153 ± 0.016 
0.182 ± 0.012
0.180 ±0.065 
0.604 ± 0 041 
0.300 ± 0.036 
0.616 ±0.054 
0.262 ± 0.048
1.030 ±0.074 
0.302 ± 0.022 
0.359 ± 0.015 
0.684 ± 0.070 
0.139 ± 0.010 
0.146 ±0.004 
0.158 ±0.016
0.142 ±0.023 
0.315 ±0.032 
0.171 ±0.017 
0.422 ± 0.059 
0.143 ±0.016 
0.903 ± 0.090 
0.099 ± 0.021 
0.186 ±0.017 
0.384 ± 0.054 
0.080 ± 0.014 
0.074 ± 0.009 
0.083 ±0.018
pit/cortex 6.150 ±0.328 6.055 ±0.702 3.973 ± 0.374 4.692 ± 0.445 5.330 ±0.923
hip/cortex 0.833 ± 0.083 0.987 ± 0.136 0.977 ± 0.056 0.958 ±0.084 1.074 ±0.081
*non-adrenalectomized rats
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Conclusions;
Estrogen. The selectivity and affinity the 11 p-ethyl-16o-[1 sF]fluoroestradiol has for the 
ER is very encouraging. One current ligand used in PET imaging of breast tumors is 16a- 
[,8F]fluoroestradiol and the lip-ethyl compound appears to be superior, in terms of the BSI, 
which would probably give greater image clarity. Clinical studies may be warranted on the 
basis of this data.
Propestins. Unfortunately, the results from the 21S-[,8F]fluoroR5020 study were not 
encouraging. The compound appears to undergo in vivo defluorination as evidenced by the 
high levels of radioactivity in the bone. The ligand might still be useful, but the 18F will have 
to be substituted in a less metabolically labile position.
Glucocorticoids. The results of the biological studies of [18F]fluoroRU28362 were rather 
discouraging. The hippocampus/cortex ratio was nearly 1:1 indicating no selective uptake. 
The pituitary/cortex ratio was somewhat higher and might provide enough contrast to use this 
compound as a pituitary imnping agent.
Experimental Section
General. Melting points (uncorrected) were determined on a Thomas-Hoover or a 
Fisher-Johns apparatus. Analytical thin-layer chromatography (TLC) was performed on Merck 
silica gel F-254 glass-backed plates. Visualization was achieved with short wave ultraviolet 
light and/or phosphomolybdic acid spray. Flash chromatography was performed according to 
Still,27 using Woelm 32-63 pm silica gel.
'H-NMR spectra were obtained on a Varian XL-200, a General Electric QE-300, a 
Nicolet NT-360, or a General Electric GN-500 spectrometer. Chemical shifts are reported in 
ppm downfield from a tetramethylsilane internal standard (8 scale). ,9F-NMR spectra were 
obtained on a Nicolet NT-360 spectrometer at 338.76 MHz and are reported downfield from
internal CFCI3. Low resolution electron impact (LREI) mass spectra were acquired from a 
Finnigan MAT-CH5 spectrometer. High resolution electron impact (HRE1) mass spectra were 
obtained on a MAT-731 instrument while a V. B. Instruments ZAB-HF mass spectrometer 
provided spectra via fast atom bombardment (FAB) employing a dithiothreitol matrix. For El 
spectra, the reported data is for an electron energy of 70 eV and is in the form: m/e (intensity 
relative to base peak = 100). Infrared (1R) spectra were obtained on a Nicolet 7199 FT-IR or 
an IBM IR/32 FI' instrument. Elemental analyses were performed by the Microanalytical 
Service Laboratory of the University of Illinois.
Analytical gas-liquid chromatography (GLC) was performed on a Hewlett-Packard 
5793A instrument equipped with flame ionization detector. Analyses were performed on an 
Alltech RSL-150 capillary column (0.25 mm X 30 m) or a Hewlett-Packard Ultra 1 capillary 
column (0.20 mm X 12.5 m). High-performance liquid chromatography (HPLC) was 
performed isocratically with a Varian 5060 or a Spectra-Physics 8700 liquid chromatograph, 
using a 5 pm analytical silica gel column (4.6 mm X 30 cm, Varian Si-5 Micro Pak), a 10 pm 
preparative silica gel column (9 mm X 50 cm, Whatman Partisil M-9), or a Cig column (10 
mm X 50 cm, Whatman Partisil M-9, ODS-2). HPLC eluent was monitored via UV 
absorbance (280 nm for estrogens, 254 nm for other steroids); for radiochemical purification, 
HPLC eluent was also monitored with a NaI(Tl) radioactivity detector. Radioactivity was 
determined in a dose calibrator.
X-ray crystallography involved diffraction experiments performed at room temperature 
with Mo radiation (X(Ka') = 0.71073 A).
Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl; all other 
solvents were distilled from CaH2. The BF3-S(CH3)2 complex was prepared by saturating 
(CH3)2S with BF3 gas.
Chemicals were obtained from the following sources and were used as received, unless 
otherwise noted: Baker, Fisher, Mallinckrodt, Aldrich, Sigma, Eastman or Alfa. 1-
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Dehydroadrenosterone was obtained from Searle Laboratories, Skokie, IL. RU 27987 and RU 
27988 were gifts of Roussel UCLAF of Paris, France. RU 28362 was purchased from 
DuPont NEN.
The following abbreviations are used: estradiol for 1, 3,5 (10)-estratriene-3, 17pdiol; 
progesterone for pregn-4-enc-3,20-dione; estrone for 1 ,3 ,5  (10)-estratriene-3-ol-17-one; SC 
16093 for 17, 17-ethylenedioxy-estra-l, 3, 5 (10)-triene-3, lip-diol; 1-dehydroadrenosterone 
for androsta-1, 4-dienc-3, 11, 17-trione; RU 27987 for 17a, 21 -dimethyl-21 S-hydroxy-19- 
nor-pregna-4, 9-diene-3, 20-dione; RU 27988 for 17a, 21-dimethyl-21S-hydroxy-19-nor- 
pregna-4, 9-diene-3, 20-dione; RU 28362 for 1 ip, 17P-dihydroxy-6-methyl-17a-propionyl- 
androsta-1,4, 6-triene-3-one.
Estrogen Synthesis: 16a-Fluoro-l ip-ethvlestra-1.3.5(10)-triene-3.17fl-diol (17) and 16a- 
fluoro-11 B-ethvlestra-1.3.5( 101-triene-3.17adiol (18)
17. 17-Ethvlenedioxvandrosta-l. 4-diene-3. 11-dione (2). 1-Dehydro-adrenostcrone 
(1) (11.45 mg, 38.4 mmol) was added to a one liter round-bottomed flask equipped with 
magnetic stirring, reflux condenser and a Dean-Stark trap. Benzene (500 mL) was added 
followed by 7.5 g (6.7 mL, 120.8 mmol) of ethylene glycol. p-Toluenesulfonic acid 
monohydrate (572 mg, 3.02 mmol) was added and the reaction mixture brought to reflux. The 
reaction was carried out under a nitrogen atmosphere. Analysis by TLC (40% EtOAc/hexane) 
indicated completion at 2 h. After cooling to room temperature, workup proceeded by 
extraction (2 X 50 mL, said. aq. Na2C03). The mixture was dried over MgSC>4 and 
concentrated in vacuo to give a pale yellow powder. Recrystallization from CH3OH/CH2CI2 
afforded (2) as needles (9.66 g, 73 %): mp 217-219°C; *H-NMR (200 MHz, CDCI3) 8 0.88 
(s, 3 H, I8-CH3), 1.45 (s, 3 H, 19-CH3), 3.77-3.96 (m, 4 H, 0C H2CH20 ), 6.05 bs, 1 H, 4- 
H), 6.20 (dd, 1 H, J = 10.3, 2 Hz, 2-H), 7.68 (d, 1 H, J = 10.3 Hz, 1-H); IR (KBr) 1703 (C- 
11 ketone), 1658 cm’1 (C-3 ketone); EIMS, 342 (M+, 7), 280 (7), 99 (100); Anal, (exact 
mass, HRE1MS) Calcd for C2,H260 4 m/e 342.1836. Found, 342.1831.
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17. 17-Ethvlenedioxv-11 ft-hvdroxvandrosta-1. 4-diene-3-one (31. A 500 mL round- 
bottomed flask equipped with a 150 mL addition funnel and magnetic stirring was evacuated 
with nitrogen after flame drying. The flask was charged with lithium tri-tert- 
butoxyaiuminohydride (13.03 g, 51.24 mmol) in THF (156 mL). Steroid (2) (7.53 g, 21.99 
mmol) was placed into the addition funnel and dissolved in THF (104 mL). The steroid in 
THF was added dropwise to the clear solution of reductant over a 65 min period. After stirring 
at room temperature for 24 h, TLC (40% EtOAc/hexane) indicated consumption of starting 
material. Workup was accomplished by dilution with water (50 mL) and extraction (150 mL, 
half-satd. sodium citrate). The aqueous layer was extracted (3 X 100 mL, EtOAc) and the 
organic layer was combined with the organic phase from the original half-satd. sodium citrate 
extraction. A brine wash of the combined organic layers preceded drying over MgS04. 
Evaporation of solvent in vacuo gave a yellow foam (7.63 g, 97%). An analytical sample was 
recrystallized from hexane/CHCb to give a coarse white powder: mp 204-206°C; *H-NMR 
(200 MHz, CDCI3) 8 1.16 (s, 3 H, I8-CH3), 1.45 (s, 3 H, 19-CH3), 3.75-3.93 (m, 4 H, 
0C H2CH20 ), 4.44 (m, 1 H, 1 la-H ), 6.02 (bs, 1 H, 4-H), 6.26 (dd, 1 H, J =  10.3, 2 Hz, 2- 
H), 7.29 (d, 1 H, J = 10.3 Hz, 1-H); IR (KBr) 3380 (OH), 1660 c m 1 (ketone); EIMS, 344 
(M+, 5), 223 (8), 99 (74), 28 (100); Anal. Calcd for C2tH2g04: C, 73.21; H, 8.21. Found:
28
C, 73.08; H, 5.96.
17. 17-Ethvlenedioxvestra-l. 3. 5 (10) trienc-3. llB -diol (4). The reaction was 
performed under a nitrogen atmosphere in a 50 mL round-bottomed flask with mechanical 
stirring. Hydroxydienone ketal (3) (800 mg, 2.32 mmol) in THF (6 mL) was added dropwise 
over a 60 min period to a dark green mixture containing biphenyl (1.43 g, 9.3 mmol), 
diphcnylmethane (781 mg, 4.6 mmol) and 25% Li in oil (773 mg, 27.8 mmol) in refluxing 
THF (10 mL). At the completion of addition, the mixture was allowed to cool to room 
temperature and was subsequently quenched with CH3OH (10 mL) followed by distilled water 
(15 mL). : he resulting two-phase system was concentrated in vacuo and added to 60 mL of
25% hexane/benzene. This solution was extracted with 5% KOH (3 X 20 mL). The combined 
basic layers were washed with 20 mL of hexane and then placed on ice. Acetic acid was added 
(15 mL) dropwise until product fell out of solution. A white paste was recovered on vacuum 
filtration. The filtrate was back extracted with 3 X 15 mL of EtOAc. The white paste was 
redissolved in EtOAc and was combined with the organic layers from the back extraction. This 
was washed with 30 mL of water and 30 mL of brine. Drying over MgSOa was followed by 
removal of the solvent in vacuo. Flash chromatography (20 cm X 60 mm Si02, 20% 
hexane/EtOAc) gave a white solid (331.8 mg, 43%): mp 193-196°C; 'H-NMR (200 MHz, 
CDCI3) 8 1.14 (s, 3 H, I8-CH3), 2.49 (bd, 1 H, J = 10.3 Hz, 9a-H ), 3.88-4.00 (m, 
0 C H 2CH20 ), 4.75 (m, 1 H, lla -H ), 6.61 (d, 1 H, J = 2.0 Hz, 4-H), 6.68 (dd, 1 H, J = 
9.3, 2.0 Hz, 2-H), 7.18 (d, 1 H, J = 9.3 Hz, 1-H); 1R (KBr) 3420 cm 1 (OH); EIMS, 330 
(M+, 8), 268 (25), 224 (19), 99 (100); Anal, (exact mass, HREIMS) Calcd for C20H26O4 m/e 
330.1831. Found, 330.1824.
17. 17-Ethvlenedioxv-3-methoxvestra-1. 3. 5 (lOM riene-llB-ol (5). DMF was 
freshly distilled and stored over sieves under argon, lodomethane (729 mg, 5.14 mmol) was 
added dropwise, as a 40% soludon (v/v) in DMF, to a stirred heterogeneous mixture of K2CO3 
(8.50 mg, 6.15 mmol) and diol (4) in DMF (6 mL) at room temperature under argon. TLC 
(20% hexane/EtOAc) indicated completion after 22 h. The reacdon mixture was poured onto 
distilled water (25 mL) and extracted (3 X 30 mL, EtOAc). The combined organic phase was 
washed with brine and dried over Na2S04. Concentration in vacuo gave a yellow oil which 
was subjected to flash chromatography (30% EtOAc/hexane, 15 cm X 35 mm Si02) to afford a 
white foam (307 mg, 89%); mp 120-122°C; >H-NMR (300 MHz, CDCI3) 8 1.14 (s, 3 H, 18- 
C H 3), 2.49 (bd, 1 H, J -  10.6 Hz, 9a-H ), 3.78 (s, 3 H, OCH3), 3.87-3.99 (m, 4 H, 
OCH2CH2O), 4.75 (m, 1 H, lla -H ), 6.66 (d, 1 H, J = 3.3 Hz, 4-H), 6.75 (dd, 1 H, J * 
8.9, 3.3 Hz, 2-H), 7.20 (d, 1 H, J = 8.9 Hz, 1-H); IR (KBr) 3420 e n r1 (OH); EIMS, 344
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(M+, 14), 282 (25), 238 (12), 211 (10), 99 (100); Anal. Calcd for C21H2804: C, 73.21; H, 
8.21. Found: C, 73.20; H, 8.07.
17.17-Ethylenedioxy-3-methoxvestra-1 .3 .5  (lO)-tricne-l 1-one (6). A 10 mL round- 
bottomed flask was charged with sterol (5) (240 mg, 0.70 mmol), in acetone (5 mL). The 
solution was brought to 0°C with an ice bath. Jones reagent was added (10 drops of 8 N 
C r03-25% aq. H2SO4), followed by 200 nL of CH3OH one min later. After 5 min, the 
reaction mixture was diluted with distilled water (10 mL), and extracted (3 X 10 mL, EtOAc). 
the combined organic layers were washed (2 X 20 mL, Satd. aq. NaHCCh). Drying over 
MgSC>4 and concentration in vacuo gave a white foam (204.1 mg, 86%) which was used 
without further purification. 'H-NMR (200 MHz, CDCI3) 8 0.88 (s, 3 H, I8-CH3), 3.52 (d, 
1 H, J « 13.4 Hz, 9a-H), 3.77 (s, 3 H, OCH3), 3.85-3.98 (m, 4 H, 0CH2CH20), 6.62 (d, 
1 H, J •  3.1 Hz, 4-H), 6.75 (dd, 1 H, J » 7.8, 3.1 Hz, 2-H), 7.26 (d, 1 H, J = 7.8 Hz, 1-H); 
1R (KBr) 1712 (ketone); EIMS, 342 (M+, 42), 298 (8), 280 (11), 99 (100); Anal, (exact mass, 
HREIMS) Calcd for C21H26O4 m/e 342.1826. Found 342.1827.
1 la-Ethvl-3-methoxyestra-l. 3.5 (lQMriene-ll6-Ql-17-QneJTt. Ketone (6) (72 mg,
0.21 mmol) was added dropwise over a ten min period to a 5 mL round-bottomed flask 
containing 6.26 11L (0.88 mmol) of EtLi (1.4 M  in benzene) in THF (1.2 mL) at -70°C. 
Magnetic stirring was employed, and the reaction was run under a blanket of argon. After 90 
min, 3 N HC1 (500 |iL) was added to the brown reaction mixture. After warming to room 
temperature, workup was performed as follows: further addition of 3 N  HC1 (500 pL), 
extraction (EtOAc), washing of combined organic layers (1 X 10 mL, water), rinsing (2 X 15 
mL satd. aq. NaHCOs) and brine wash. Drying over MgS04 was followed by concentration 
in vacuo to give a yellow oil. This oil was dissolved in acetone (1 mL) and placed on ice. 3 N 
HC1 (3 mL) was added and the mixture was allowed to stir overnight as it warmed to room 
temperature (12 h). Extraction (EtOAc) v/as followed by water (1 X 10 mL) then satd. aq.
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NaHCOj (2X 15  mL) rinses and brine wash. Drying over MgS04 followed by concentration 
in vacuo gave a purple oil which was subjected to flash chromatography (30% EtOAc/hexane). 
A purple solid was isolated (32 mg, 46%): mp 119-122°C; !H-NMR (300 MHz, CDCI3) 8 
1.01 (t, 3 H, J = 8.2 Hz, CH2CH3), 1.13 (s, 3 H, I8-CH3), 2.33 (d, 1 H ,J  = 9.8 Hz, 9a- 
H), 3.81 (s, 3 H, OCH3), 6.72 (m, 2 H, 4-H and 2-H), 7.69 (d, 1 H, J = 9.8 Hz, 1-H); IR 
(KBr) 3550 (OH), 1736 c m 1 (ketone); EIMS, 328 (M+, 62), 256 (27), 160 (100), 134 (59). 
97 (84): Anal. Calcd for C21H28O3: C, 76.78; H, 8.61. Found C, 77.01; H, 8.54.
3-Mcthoxy-11 -ethvlestra-1.3.51101.9( 1 ll-tetraene-17-onc (8). Steroid (7) (715 mg, 
2.18 mmol) was dissolved in 25 mL of benzene in a 100 ml- round-bottomed flask equipped 
with a reflux condenser and nitrogen inlet. p-Toluenesulfonic acid monohydrate (286 mg, 
1.50 mmol) was added and the mixture was heated at reflux for 10 min, at which time GLC 
indicated consumption of starting material and formation of two products. Workup involved 
dilution (EtOAc, 20 mL) and rinsing (2 X 20mL, saturated aqueous NaHCCh). The aqueous 
layer was washed (1 X 20 mL, EtOAc), the organic layers were combined, washed with brine, 
and dried (Na2S04). Concentration in vacuo was followed by flash chromatography (5% 
EtOAc/hexane, 31 cm X 42 mm Si02) to provide the major product as a clear oil which 
solidified on standing (367 mg, 54%): mp 78-80°C; 'H-NMR (200 MHz. CDCI3) 60.92 (s, 
3H, I8-CH3), 1.10 (t, 3H, J -  7.5 Hz, CfyCfcb). 3.81 (s, 3H, OCH3). 6.70 (bs. IH. 2-H). 
7.24 (d, 1H, J = 8.2 Hz, 1-H); IR (CHCI3) 1727 cm 1 (ketone); EIMS. 310 (M+, 22), 
219(100), 177(42), 173(38), 145(61); Anal, (exact mass, HREIMS) Calcd forC2|H2602 m/e 
310.1933. Found, 310.1933.
3-Methoxv-l lfl-ethvlestra-1.3 101-trienc- 17-one (9) and 3-Methoxv-1 la-cthvlcun-
1.3-5n01-trienc-17-one. Tetraene (8) (938 mg, 3.03 mmol) was dissolved in 64 mL of 20% 
EtOAc/methanol in a 250 mL round-bottomed flask. 5% Pd/C (200 mg) was added and the 
mixture vigorously strirred under hydrogen at 1 atm for 31 h, at which time GLC indicated 
consumption of starting material and production of 9 and 9'(1 la-ethyl) in a ratio of 2.6:1
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respectively. The reaction mixture was filtered through neutral alumina (7 cm X 25 mm) then 
through filter paper. Concentration in vacuo gave a yellow foam (902 mg, 96%) which was 
used without further purification. Previous partial separation of the crude mixture via 
preparative TLC (5:3:2 CHCI3, hexane, CH2CI2, 7 developments) revealed two major 
products:
(9) : GLC tR, 6.52 min; 'H-NMR (500 MHz, CDCI3) 6 0.91 (t, 3H, J -  7.6 Hz, 
CH2CII3), 1.04 (s, 3H, I8-CH3), 3.78 (s, 3H, OCH3), 6.62 (d, 1H, J = 2.1 Hz, 4-H), 6.73 
(dd, 1H, J = 9.5, 2.1 Hz, 2-H), 7.08 (d, 1H, J = 9.5 Hz, 1-H); EIMS, 312 (M \ 100), 285 
(6), 257 (7), 199 (84), 186 (41), 184 (25), 160 (46), 91 (16).
(9’(1 la-ethyl)): GLC tR, 5.54 min; ’H-NMR (500 MHz, CDCI3) 8 0.98 (t, 3H, J = 
8.5 Hz, CH2CH3), 1.00 (s, 3H, I8-CH3), 3.78 (s, 3H, OCH3), 6.67 (dd, 1H, J = 8.4, 2.1 
Hz, 2-H), 6.69 (d, 1H, J -  2.1 Hz, 4-H), 7.73 (d, 1H, J -  8.4 Hz, 1-H); EIMS, 312 (M+, 
100), 199 (72), 186 (31), 184 (16), 160 (43).
11 B-cth vlcstra-1,3.5( 101-triene-3-ol-17 -one (10) and 1 la-eth vlestra-1.3.5(1 Q)-triene-3- 
ol-17-one. A mixture containing (9) and (9') (902 mg, 2.84 mmol) was dissolved in 42 mL of 
freshly distilled CH2CI2 in a 100 mL round-bottomed flask. The solution was cooled to 0°C  
and 5.3 mL of BF3-S(CH3>2 (vide supra) was added. The reaction mixture was allowed to 
warm to room temperature as it reacted and was quenched at 24 h with ice-water (40 mL). The 
heterogeneous mixture was washed with saturated aqueous NaHC03 (50 mL), the layers 
separated and the aqueous layer extracted (3 X 50 mL, CH2CI2). The combined organic layers 
were washed with brine and dried (Na2S04). Concentration in vacuow&s followed by ether 
trituration to provide (10) as a white powder (490 mg, 57%), an analytical sample of which 
was recrystallized from acetone/hexane to afford white needles; (10'(1 la-ethyl)) remained as 
the soluble component and produced a yellow foam (209 mg, 24%):
(10) : mp 250-254°C; JH-NMR (500 MHz, CDCI3) 8 0.89 (t, 3H, J = 7.4 Hz, 
CH2CH3), 1.05 (s, 3H, 18-CH3), 4.60 (s, 1H, OH), 6.53 (d, 1H, J -  2.1 Hz, 4-H), 6.66
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(dd, 1H, J -  10.6,2.1 Hz, 2-H), 7.04 (d, 1H, J -  10.4 Hz, 1-H); IR (KBr) 3340 (OH), 1719 
cm-* (ketone); EIMS, 298 (M+, 100), 296 <!?', 185 (47), 172 (28), 170 (12), 146 (36); Anal. 
Calcd for C20H2i O2: C, 80.48; H, 8.80. Found C, 80.40; H, 8.72.
(10’): ‘H-NMR (300 MHz, CDCI3) 5 0.96 (t, 3H, J = 7.36 Hz, CfyCfib), 1.00 (s, 
3H, I8-CH3), 4.60 (bs, 1H, OH), 6.61 (dd, 1H, J = 8.2, 5.1 Hz, 2-H), 6.62 (bs, 1H, 4-H), 
7.27 (d, 1H, J -  8.2 Hz, 1-H); IR (CHCI3) 3390 (OH), 1730 c n r1 (ketone); EIMS, 298 (M+, 
60), 185 (44), 172 (36), 146 (100), 97 (12); Anal, (exact mass, HREIMS) Calcd for 
C20H26O2 m/e 298.1932. Found, 298.1936.
The remainder of the synthesis was elaborated upon by another worker in this laboratory.16 
Progestin Syntheses; 21rt-Fluoro-17a.21-dimethvl-19-nor-prcgna-4.9-diene-3.20-dione (271 
and 21 S-Fluoro-17ct.21 -dimethyl-19-nor-prcgna-4.9-dicne-3.2Q-dione (28).
3.3-Ethylcncdioxy-1 7cl2 1 -dimethvl-2l/Mivdroxv- 14-nor-pregna-5(l 01.9( 111-diene- 
20-one (21) and 3.3-ethvlenedioxv-17a.21-dim ethvl-21S-hvdroxv-14-nor-pregna- 
5(10).9(1 l)-diene-20-one (22). RU27987 (19) (25 mg, 73 pmol for synthesis of (21)) or 
RU27988 (20) (25mg, 73 pmol for synthesis of (22)) was dissolved in a mixture of ethylene 
glvcol (98 pL, 1.8 mmol) and triethyl orthoformate (97 pL, 0.58 mmol) After addition of p- 
toluenesulfonic acid monohydrate (1.4 mg, 7.3 pmol) the green reaction mixtures were allowed 
to stir at room temperature for 5 min at which time triethylamine (4.8 pL, 34 pmol) was added, 
discharging the green color. Each reaction mixture was then poured onto saturated NaHCOs, 
extracted with ether and dried (Na2SC>4). Flash chromatography (40% EtOAc/hexane, 16 cm 
x 25 mm S i0 2) provided white solids in each case, each able to be recrystallized from 
isopropyl ether:
(21) 22.5 mg, 80%, white solid, mp 132-133°C; •H-NMR (300 MHz, CDCI3) 8 0.64 
(s, 3H, I8-CH3), 1.19 (s, 3H, I70-CH3), 1.32 (d, 3H, J -  6.4 Hz, 21-CH3), 2.98 (d, 1H, J 
-  9.54, OH), 3.99 (s, 4H, 0C H2CH20 ), 4.41 (dq, 1H, J = 9.5, 6.5 Hz, 21R-H), 5.58 (m, 
1H, 11-H); IR (KBr) 3410 (OH), 1700 (ketone), 1370 c m 1; EIMS, 386(M+, 21), 313 (26),
33
227 (14), 99 (18), 95 (100), 43 (15); Anal Calcd for C24H34O4: C, 74.54; H, 8.88. Found: 
C, 74.5 H, 8.86.
(22) 21.3 mg, 75%, white plates, mp 144-45°C;‘H-NMR (300 MHz, CDCI3) 8 0.63 
(s, 3H, I8-CH3), 1.15 (s, 3H, 17a-CH3), 1.31 (d, 3H, J = 7.0 Hz, 21-CH3), 3.71 (d, 1H, J 
= 6.5, OH), 3.98 (s, 4H, 0C H2CH20 ), 4.54 (quintet, 1H, J = 6.7 Hz, 21.^-H), 5.57 (m, 1H, 
11-H); IR (KBr) 3410 (OH), 1700 (ketone), 1370 cm '; EIMS, 386 (M+, 100), 313 (32), 
227(17), 99(25), 95 (99), 45 (20); Anal Calcd for C24H3404: C, 74.54; H, 8.88. Found: C, 
74.57; H, 8.93.
3.3-Ethvlenedioxv-21Sif (trifluoromethvl)sulfonvlloxvl- 17a.21 -dimethyl-19-
n o rp re g n a - 5 ( 1 0 ) .9 ( l  n - d io n e - 2 0 - o n e ___ (21 )___ &Jld___ 3 .3 - e th v le n e d io x v -
21/gf Ktrifluorometh vDsulfonvl ioxy 1-17a.21 -dimethyl-19-norprcgna-5( 101.9C 11 l-dione-20- 
one (241 Ketol (21) or (22) (49 mg, 0.13 mmol) was dissolved in freshly distilled CH2CH2 
(1.5 mL) and cooled in a CCtyiPrOH bath. Triflic anhydride (6.5 pL, 39 pmol) was added 
followed by 2,6-lutidine (33 pL, 0.19 mmol) and each reaction mixture was allowed to stir for 
1 h at which time each was diluted ith cold CH2C12. Passage through a 2 cm plug of cold 
neutral alumina (CCh jacket) gave a brownish oil in each case which was subsequently purified 
by flash chromatography (25% EtOAc/hexane, 20 cm x 25 mm SiCh) to give white foams.
(23) 44.2 mg, 66%; 'H-NMR (300 MHz, CDCI3) 8 0.67 (s, 3H, I8-CH3), 1.20 (s, 
3H, 17a-CH3), 1.64(d, 3H, J = 6.6 Hz, 21-CH3), 3.99 (s, 4H, 0C H2CH20 ) , 5.53 (q, 1H, 
J -  6.6 Hz, 21R-H), 5.59 (m, 1H, 11-H); EIMS, 518 (M+, 54), 195(38), 171 (50), 99 (83), 
95 (100), 91 (45), 86 (66), 57 (56), 43 (64); Anal (exact mass, HRE1MS) Calcd for 
CMH33SO6F3 m/e 518.1950. Found, 518.1963.
(24) 43.4 mg, 67%; ‘H-NMR (300 MHz, CDCI3) 8 0.69 (s, 3H, I8-CH3), 1.20 (s, 
3H, 17ct-CH3), 1.66 (d, 3H, J = 6.9 Hz, 21-CH3), 3.99 (s, 4H, 0C H2CH20 ) , 5.52 (q, 1H, 
J = 7 Hz, 21S-H), 5.59 (m, 1H, 11-H); EIMS, 518 (M+, 28), 195(31), 171 (40), 99 (68),
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95 (100), 91 (40), 86 (50), 57 (54), 43 (28); Anal (exact mass, HREIMS) Calcd for 
C25H33SO6F3 m/e 518.1950. Found, 518.1948.
3.3-Eth vlenedioxv-21 ft-fluoro-17a.21 -dimethyl-19-norpregna-5( 10).9( 11 )-diene-20- 
one (251 and 3.3-Ethylcnedioxv-21S«fluoro-17a.21-dimethvl-19-norpregn a -5 n 0 ).9 ( in -  
diene-20-one (261. Triflates (23) and (24) (94 mg, 84 nmol) were dissolved in THF (2.5 
mL) and nBu4NF (1 M in THF, 76 pL, 76 nmol) was added. The reaction mixture was 
allowed to stir at room temperature for 15 min at which time solvent was removed in vacuo. 
The oils were then passed down a 2 cm column of neutral alumina and the residue subjected to 
flash chromatography (25% EtOAc/hexane, 24 cm x 25 mm S i02) producing a clear oil in each 
case.
(25) 22.1 mg, 67%; *H-NMR (300 MHz, CDCI3) 8 0.67 (s, 3H, I8-CH3), 1.21 (s, 
3H, 17a-CHi), 1.50 (dd, 3H, J = 17, 6.9 Hz, 21-CH3), 3.99 (s, 4H, OCH2C H2C), 5.09 
(dq, 1H, J = 50, 6.8 Hz, 21S-H), 5.58 (m, 1H, 11-H); ,9F-NMR (338 MHz, CDCIj) *- 
180.64 (dq, J = 46, 24 Hz, 21/?-F); EIMS, 388 (M+, 100), 360 (49), 315 (46), 171 (54), 99 
(50), 95 (96), 43 (34); Anal (exact mass, HREIMS) Calcd for C24H3303Fm /e 388.2414. 
Found, 388.2428.
(26) 24.2 mg, 75%; *H-NMR (360 MHz, CDCI3) 8 0.67 (s, 3H, I8-CH3), 1.18 (s, 
3H, 17a-CH3), 1.48 (dd, 3H, J -  18, 6.5 Hz, 21-CH3), 3.98 (s, 4H, OCH2CH20 ), 5.12 
(dq, 1H, J = 48, 6.5 Hz, 21R-H), 5.58 (m, 1H, 11-H); 19F-NMR (338 MHz, CDCI3) <p - 
180.32 (dq, J = 46, 22 Hz, 21S-F); EIMS, 388 (M+, 100), 360 (45), 315 (38), 171 (49), 99 
(49), 95 (100), 43 (23); Anal (exact mass, HREIMS) Calcd for C ^H ^C ^F  m/e 388.2414. 
Found, 388.2428.
21 /?-Fluoro-17a .21 -dimethyl- 19-nor-prcgna-4.9-diene-3.20-dione (27) and 215- 
Euoro-17tt.21-dimethvl-19-nor-prcgna-4.9-diene-3.20-dione (28). Fluoride (25) or (26) (20 
mg, 51nmol) was dissolved in 700 nL of acetone. Concentrated sulfuric acid (two drops, ~20 
pL) was added and each reaction mixture was allowed to stir at 60°C for 5 min. Ditlution with
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1 mL water was follwed by ether extraction, drying (Na2S04> and passage through a 2 cm 
plug of neutral alumina. Flash chromatography (35% EtOAc/hexanr 70 cm x 25 mm Si02) 
gave (27) as a clear oil and (28) as a brownish solid, (11 mg, 63% in each case).
(27) : ’H-NMR (300 MHz, CDCI3) 8 0.86 (s, 3H, I8-CH3), 1.20 (s, 3H, 17a-CH3), 
1.50 (dd, 3H, J = 24, 6.9 Hz, 21-CH3), 5.10 (dq, 1H, J = 50, 6.9 Hz, 21.V-H), 5.67 
(ms,lH, 4-H); 19F-NMR (338 MHz, CDC13)4>-180.46 (dq, J = 49, 24 Hz, 21// F); EfMS, 
344 (M+, 87), 269(100), 213 (38), 159 (39), 107 (48), 95 (40;, 91 (40); Anal (exact mass, 
HRE1MS) Calcd for C22H2902Fm /e 344.2142. Found, 344.2141.
(28) : mp 121-124°C; 'H-NMR (300 MHz, CDC13) 8 0.85 (s, 3H, I8-CH3), 1.27 (s, 
3H, 17u-CH3), 1.48 (dd, 3H, J = 24, 0.5 Hz, 21-CH3), 5.06 (dq, 1H, J = 48, 6.6 Hz, 21/?- 
H), 5.68 (brs.lH, 4-H); ,91 NMR (338 MHz, CDCh) 4. -179.98 (dq, J = 41, 21 Hz, 21S-F); 
EIMS, 344 (M+, 48), 769(57), 213 (23), 159 (35), 107 (34), 95 (26), 91 (29); Anal (exact 
mass, HREIMS) Calcd for C22H29O2F nVe 344.2152. Found, 344.2158.
Glucocorticoid Synthesis: 17a-13,-Fluoropropvnvni-l lg.l7p-dihvdroxy-6-methvl-andrQgta- 
1.4.6-triene-3-one (35).
6o-Methyl-11 B-hvdroxv-androsta-1,4-diene-3.17-dione (301. 6a-Methylpredinsolone
(29) (1.5 g, 4.00 mmol) was dissolved in 50% aqueous acetic acid (144 mL) and placed under 
nitrogen. Sodium bismuthate (6.9 g, 24.8 mmol) was added and the mixture was stirred for 5 
h at room temperature. The mixture was extracted (2 x 200 mL CHCI3) and the organic layers 
were combined, washed with saturated aqueous NaHC03 (3 x 150 mL) and brine (150 mL), 
and dried (Na2S04). Concentration in vacuo followed by flash chromatography (60% 
EtOAc/hexane, 20 cm x 40 mm S i02) gave a white solid (1.20 g, 96%): mp 247°C; ’H-NMR 
(300 MHz., DMSO-d6) 8 1.04 (s, 3H, I8-CH3), 1.04 (d, 3H, J = 5.9 Hz, 6a-CH3), 1.38 (s, 
3H, 19-CH3), 4.22 (m, 1H, lla -H ), 4.78 (d, J -  3.1 Hz, -OH), 5.79 (d, 1H, J » 1Hz, 4-H), 
6.12 (dd, 1H, J = 10, 1.2 Hz, 2-H), 7.27 (d, 1H, J = 10 Hz, 1-H); 1R (KBr) 3440 (OH),
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1735, 1658 (C=o 17-ketone), 1620, 1600, 1412 c m 1; EIMS, 314 (M+, 3), 136(100), 
121(17), 91(9); Anal Calcd for C20H25O3: C, 76.40; H, 8.33. Found: C, 76.27; H, 8.25.
6a-Methvl- l ip-hvdroxv-andro5ta-1.4.6-triene-3.17-dione (31). Dione (30) (2.70 g, 
8.59 mmol) was dissolved in 2-pentanol (145 mL) in a 250 mL round-bottomed flask equipped 
with a reflux condenser, magnetic stirring, and a nitrogen inlet. Chloranil (12.71 g, 51.7 
mmol) was added followed by approximately 4 g of CaCOj and the mixture was stirred as it 
was heated at reflux for 5 h. The mixture was allowed to cool to room temperature, filtered, 
and concentrated in vacuo. The reddish-orange residue was redissolved in ~200 mL of 
CHCI3,washed with H2O (4 x 200 mL), 5% aqueous NaOH(5 x 100 mL), H2O (5 x 200 mL), 
and brine (200 mL), and dried (Na2SC>4). Concentration in vacuo was followed by flash 
chromatography (50% EtOAc/hexane, 20 cm x 70 mm SiCh) to give a yellow solid (1.83 g, 
68%): mp 198-200°C; ‘H-NMR (300 MHz, CDC13)S  1.23 (s, 3H, I8-CH3), 1.43 (s, 3H, 
I9-CH3), 1.92 (s, 3H, 6-CH3), 4.51 (m, 1H, lla -H ), 5.97 (s, 1H, 4-H), 6.15 (s, 1H, 7-H), 
6.32 (dd, J = 9.8, i.2 Hz, 2-H), 7.31 (d, J -  9.8 Hz, 1-H); IR (KBr) 3410 (OH), 1730 (d), 
1658 (C=0, 17-ketone), 1615 (C=0, 3-ketone), 1409 cm-i; EIMS, 312 (M+, 66), 294 (59), 
279(43), 185(100), 159(41); Anal Calcd for C20H24O3: C, 76.89; H, 7.74. Found: C, 
76.55; H, 7.87.
17a-13'-(2-Tetrahvdropyranvl)1-11 a. 17B-dihvdroxv-6-meth vl-androsta-1.4.6-triene-3- 
one (321. Propargyltetrahydropyranyl ether (475 pL, 3.52 mmol) in pentane (18 mL) was 
placed in a flame-dried 50 mL 2-necked round-bottomed flask under nitrogen and was cooled 
to 0°C in an ice/salt bath. BuLi (2.27 mL, 3.52 mmol) was added and a white precipitate 
formed. Dione (31) (500 mg, 1.60 mmol) in THF (10 mL, freshly distilled) was added to the 
flask and the mixture was allowed to stir for 5 h. The reaction mixture was quenched with 
saturated aqueous NH4CI (50 mL) and extracted (3 x 50 mL EtOAc). The combined organic 
layers were washed with H2O (50 mL), brine (50 mL), and dried (Na2S04). Concentration in 
vacuo was followed by flash chromatography (60% EtOAc/hexane, 20 cm x 40 mm Si02) to
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give a yellow oil (230 mg, 31%). ‘H-NMR (300 MHz, CDCI3) « 1.20 (s, 3H, I8-CH3), 1.41 
(s, 3H, I9-CH3), 1.91 (s, 3H, 6-CH3), 3.47 and 3.79 (m, 2H, -OCH2 o f THP), 4.26 (d, 2H, 
J -  4.6, C »C C H20 ) , 4.50 (brs, 1H, llo -H ), 4.73 (d, 1H, J = 1.6 Hz, -OCHO), 5.87 (s, 
1H, 4-H), 6.13 (s, 1H, 7-H), 6.31 (dd, J = 10, 1.2 Hz, 2-H), 7.31 (d, J -  10 Hz, 1-H); IR 
(KBr) 3430 (OH), 2920, 2875, 1650 (C=0, ketone), 1600, 1020 c m 1; FABMS, 453(M++H, 
100), 369(35), 309(33), 185(68), 155(100), 135(87), 119(100); Anal (exact mass, 
HRFABMS) Calcd for Cm^ sO j : m/e (+H) 453.2641. Found: 453.2641.
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l7ct-f3'-hvdrooxvproDvnvl1l-llB.l7B-dihvdroxv-6-methvl-androsta-l.4.6-triene-3-one 
(331. Ether (32) (63.1 mg, 0.139 mmol) was dissolved in THF (1 mL, freshly distilled). 
Water (3 mL) was added followed by HOAc (3 mL). The reaction mixture was stirred at 50°C 
for 4 h. After cooling to room temperature, dilution with water (5 mL) was followed by 
pouring the reaction mixture onto saturated aqueous NaHCCb (10 mL), extraction ( EtOAc, 2 x 
15 mL), and drying (Na2S(>4). Concentration in vacuo followed by flash chromatography 
(EtOAc, 20 cm x 30 mm SiO^ gave a colorless oil (38.3 mg, 75%): 'H-NMR (300 MHz, 
CD3CN) 6 1.11 (s, 3H, I8-CH3), 1.38 (s, 3H, 19-CH3), 1.89 (d, 3H, J = 1.6 Hz, 6-CH3), 
4.10 (s, 2H, C»CCH20 ) , 4.39 (d, 1H, J = 2.1 Hz, lla -H ), 5.96 (s, 1H, 4-H), 6.01 (s, 1H, 
7-H), 6.20 (dd, J «  9.9, 1.6 Hz, 2-H), 7.34 (d, J -  9.9 Hz, 1-H); IR (KBr) 3400, 2980- 
2870, 1645 (C -O , ketone), 1600, 1035 c m 1; EIMS, 368(M+, 8), 317(17), 185(47),
159(100), 135(43), 85(36); Anal (exact mass, HREIMS) Calcd for C ^ H ^ O ^  m/e 368.1988. 
Found: 368.1980.
17a-f3,-methanesulfonvloxvDropvnvlll-llB.17B-dihvdroxv-6-methvl-andiosta-1.4Ar 
trienc-3-one (341. Triol (33) (42.7 mg, 0.12 mmol) was dissolved in THF (1.3 mL, f  eshly 
distilled), and the solution was cooled to 0°C. Triethylamine (31 pL, 0.22 mmol) was added, 
followed by a solution of mesyl chloride in THF (0.21 mmol, 10%, v/v). After stirring at 0°C 
for 2 h, and additional 8 pL (57 pmol) o f triethylamine was added followed by 4 pL (52 pmol) 
of MsCI. After 30 min further, the cloudy reaction mixture was diluted with ice-water and
extracted ( EtOAc). Brim wash and drying (Na2SQ«) were followed by concentration in vacuo 
then flash chromatography (80% EtOAc/hexane, 23 cm x 30 mm SiCh) which afforded a 
brownish oil (32.1 mg, 62%); ‘H-NMR (300 MHz, CDC13) 8 1.22 (s, 3H, I8-CH3), 1.41 (s, 
3H, 19-CH3), 1.91 (s, 3H, 6-CH3), 3.06 (s, 3H, SO2CH3), 4.51 (brs, 1H, lla -H ), 4.84 (s, 
2H, C «C CH20 ), 5.86 (s, 1H, 4-H), 6.14 (s, 1H, 7-H), 6.31 (dd, J -  10.2, 1.3 Hz, 2-H),
7.31 (d, J ■ 10.2 Hz, 1-H); FABMS, 447(M++H, 100), 309(90), 195(40), 155(100), 
135(100), 119(100); Anal (exact mass, HRFABMS) Calcd for C24H3oS 0 4: mI t  (+H) 
447.1823. Found: 447.1832.
17a-r3'-Fluoropropvnvni-l IB- 17B-dihvdroxv-6-methvl-androsta- lA6-tricne_-3-one 
(351. Mesylate (34) (12.6 mg, 28.2 mmol) was dissolved in THF (0.540 mL, freshly 
distilled). n-Bi^NF (1 M  in THF, 102 pL, 0.102 mmol) was added and the reaction mixture 
was heated at 60°C for 20 min. After cooling to room temperature, the reaction mixture was 
passed through a 3 cm plug of neutral alumina. Concentration in vacuo was followed by flash 
chromatography (40% EtOAc/hexane, 16 cm x 10 mm Si02) to produce a light yellow oil 
(10.4 mg, 28.1 pmol, 100%); ‘H-NMR (300 MHz, CDCI3) 8 1.22 (s, 3H, I8-CH3), 1.41 (s, 
3H, I9-CH3), 1.91 (s, 3H, 6-CH3), 4.52 (d, 1H, J -  2.7 Hz, llo -H ), 4.96 (d, 2H, J = 47.5 
Hz, C «C C H2F), 5.87 (s, 1H, 4-H), 6.14 (s, 1H, 7-H), 6.31 (dd, J -  10.2, 1.8 Hz, 2-H),
7.32 (d, J -  10.2 Hz, 1-H); 19F-NMR (338 MHz, CDCI3) *-214.62 (t, J -  47.8 Hz, CH2F); 
EIMS, 370(M+, 7), 252(10), 237(17), 203(46), 185(29), 159(100), 135(44), 91(24), 41(27); 
Anal (exact mass, HREIMS) Calcd for C23H2t03F: m/e 370.1944. Found: 370.1951.
Radiochemical Synthesis
General. Fluorine-18 was prepared from [180 ]  H20  by the u O (p,n) ,8F reaction. 
Tetrabutylammoniumhydroxide (1 M  in in water (unless otherwise indicated), ~3 pmol) was 
added via Hamilton syringe to die bottom of a Vacutainer*. Water containing 18F-fluoride was 
added to the base followed by acetonitrile (200 pL). The solution was then heated in an oil
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bath at 110°C while a gentle stream of nitrogen assisted in the azeotropic removal of water. 
When almost dry, heat was removed and an additional 200 pL of acetonitrile was added for a 
second azeotropic distillation. Once nearly dry, the Vacutainer® was removed from the oil bath 
and the final segment of the evaporation was performed without heat The reaction solvent was 
then added to the Vacutainer* and the resolubilized fluoride was transferred to a borosilicate 
glass vial (15 mm x 45 mm, teflon-lined cap) containing 1-2 mg of substrate. The entire 
process requires ~10 min and ~80% of the initial activity is transferred. Yields given are only 
for reactions in which isolated activity was used for in vivo experiments; yield ranges for 
smaller activity scale reactions are shown parenthetically. Activity collected is uncorrected for 
de^ay while yield (and yield ranges) are corrected. All reactions are with no carrier added 
HPLC injection volume was 1 mL. Identity of the radiolabeled compounds was confirmed by 
coelution with authentic unlabeled standards on HPLC. Specific activities were determined by 
a competitive radiometric binding assay.28
21/?-fl8FlFluoro-17a.21-dimethvl-19-nor-nreyn-4.9 diene-3.20-dione (flflFl 27) and 
21 S-fllF IF luoro -17a .2 1 -dimethyl- 19-nor-oregn-4.9-diene-3.20-dione ffl&Fl 28). The 
reaction employed 1.41 mg (2.8 pmol) of triflate (25) or (26) and 3.1 pL of nBtuNOH. 
Activity (120 mCi) was transferred in THF (500 pL). After 10 min at room temperature, 
solvent was removed under a gentle stream of nitrogen, the residue dissolved in acetone (500 
pL) and 20-25 pL o f concentrated H2SO4 (2 drops) was added. The reaction mixture was 
stirred at 60°C for 7-8 min at which time it was diluted with water (1.5 mL) and extracted (2 x 
1.5 mL ether). The ether layer was passed through a 3 cm plug of Na2S04, blown down 
under nitrogen, and the residue was redissolved in 1,2-dichloroethane prior to injection on the 
HPLC [Whatman M -9,87% hexane/13% (5% /P1OH/CH2CI2), 5 mL/min],
([18F] 27): 30.2 mCi, 34% (39-56%); tR -  16 min; SA -  1060 Ci/mmol.
([i«F] 28): 8.8 mCi, 12% (12-50%); tR -  16 min; SA * 740 Ci/mmol.
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17a-f3'-fl8Fi-Fluoropropvl1-llB.17B-dihvdroxv-6-mcthvl-androsta-1.4.6-triene-3-Qne 
ffilF l  35V The reaction employed 1.45 mg (3.25 prnol) o f mesylate (?) and 3 pL of 
nBaiNOH in the resolubilization. Activity (192 mCi) was transferred to substrate in THF (200 
pL). Reaction conditions and workup were identical to those in the synthesis of [tsF]27 and 
28 above (from mesylate (34)). Purification via  HPLC (Whatman M-9, 90% (5% 
<PiOH/CH2Cl2/10% hexane), 5 mL/min], gave 5.34 mCi, 4.6% (3.4-19%), tR -  17 min; SA -  
68 Ci/mmol.
In Vivo Biodistribution Studies. The protocol used in uptake studies involving tritiated 
steroids has been detailed elsewhere,29 and the technique used for tritiated RU28362 was 
similar. Briefly, the rats were adrenalectomized several days prior to the experiment. 
[3H]RU28263 were prepared in 20% ethanol/saline and were injected via the carotid artery 
with the animals under ether anaesthesia. At the indicated times, animals were decapitated, 
blood and organs were removed, weighed and counted. Receptor-mediated uptake was 
demonstrated by co-injection with unlabeled blocking compound (~18 pg/animal).
After HPLC purification, the fluorine-18 labeled compounds were concentrated in 
vacuo, dissolved in a small volume of ethanol (-200 pL) and that solution was filtered through 
an ethanol-wetted Aerodisc-LC13 (Millipore) filter. The vessel containing the fluorine-18 
labeled steroid was rinsed with 200 pL of saline and the rinsings passed through the filter to 
give a total volume of 400 pL of 1:1 ethanol/saline. Further dilution was necessary to achieve 
the desired dosage (~15 pCi or ~100 pCi/100 pL <20% ethanol/saline). Anaesthetised animals 
were injected intravenously via the femoral vein, were decapitated at the indicated times and 
blood and organs were removed, weighed and counted. Receptor-mediated uptake was 
ascertained as described above. In experiments in which the effect of tamoxifen pre-treatment 
was ascertained, rats were injected subcutaneously with 200 pg tamoxifen/animal on each of 
the three days preceding the experiment. Experiments involving progestins and estrogens
employed immature Sprague female rats (~24 days old). Assessment of corticosteroid uptake 
was determined in adrenalectomized (4-8 days prior to the experiment) male Sprague-Pauley 
rate (). Adrenalectomized animals were maintained on 0.9% NaG.
in  Vitro Studies. Receptor binding affinities were measured either directly, in the case of 
[3H2]-RU28362 which was available in radiolabeled form, or indirectly (all other cases). 
When measured directly, specific target receptor-mediated and non-specific binding were 
displayed in terms of a Scatchard plot30 in order to facilitate calculation of the equilibrium 
association constants.31 Indirect measurements of affinity were obtained through competitive 
binding assays and a relative binding affinity (RBA), e.g, relative to 100 for estradiol in the 
estrogen series, was calculated. In competitive binding assays, increasing concentrations of 
the non-radiolabeled test compound were added to a series of incubations containing receptor 
and a fixed, receptor-saturating concentration of the appropriate tritiated steroid. Both direct 
and indirect methods rely on a differential dissociation of ligand from low-affinity, non-specific 
and high-affinity, specific sites and therefore represent non-equilibrium (dynamic) systems.
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